TrialsgrambetaRCTs are beautiful

Gynaecologic cancers

PARP-inhibitor maintenance in BRCA/HRD-positive ovarian cancer and immunotherapy in cervical and endometrial cancer.

  • 2018SOLO-1⁠BRCA-mutated ovarianIn 391 patients with newly diagnosed BRCA1/2-mutated advanced ovarian cancer in response to first-line platinum, maintenance olaparib for two years improved progression-free and overall survival compared with placebo.HR 0.3Read →